Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Free Report) Director Troy Edward Wilson sold 27,000 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $3.33, for a total value of $89,910.00. Following the sale, the director now owns 350 shares in the company, valued at approximately $1,165.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Puma Biotechnology Price Performance
Shares of Puma Biotechnology stock opened at $3.09 on Thursday. Puma Biotechnology, Inc. has a twelve month low of $2.13 and a twelve month high of $7.73. The stock has a market capitalization of $149.06 million, a P/E ratio of 9.36 and a beta of 1.04. The company has a current ratio of 1.46, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07. The business’s fifty day moving average price is $4.36 and its 200 day moving average price is $4.85.
Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.12. Puma Biotechnology had a return on equity of 35.49% and a net margin of 6.79%. The firm had revenue of $43.80 million for the quarter, compared to analysts’ expectations of $41.53 million. As a group, research analysts anticipate that Puma Biotechnology, Inc. will post 0.22 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
PBYI has been the topic of several analyst reports. StockNews.com upgraded Puma Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, June 12th. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Monday, June 3rd.
Get Our Latest Research Report on Puma Biotechnology
Puma Biotechnology Company Profile
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Featured Articles
- Five stocks we like better than Puma Biotechnology
- Market Cap Calculator: How to Calculate Market Cap
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- How to Invest in the Best Canadian StocksĀ
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- 5 Top Rated Dividend Stocks to Consider
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.